FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 309:1347-1353 December 1, 1983 Number 22 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Fifty-one patients with acute nonlymphocytic leukemia (16 with end-stage disease, 17 in second or third remission or in early relapse, and 18 in first remission) were given infusions of HLA-identical sibling marrow after cytoreduction with high doses of busulfan and cyclophosphamide. Actuarial two-year survival rates were 0 per cent, 29 per cent, and 44 per cent, respectively. Twelve patients are still alive and in remission after 327 to 1488 days, with 10 surviving beyond two years. Acute graft-versus-host disease and viral pneumonia were the major causes of death. Leukemic cells failed to clear in one patient with end-stage disease, and a relapse with meningeal leukemia occurred in another. Only one other relapse was seen--in a patient given a transplant during a third remission. Survival was favorably affected by younger age and transplantation during first remission. We conclude that high-dose chemotherapy with busulfan and cyclophosphamide, followed by allogeneic-marrow transplantation, can produce long-term remission of acute leukemia. Chemotherapy with high-dose busulfan and cyclophosphamide before transplantation provides an effective alternative to cyclophosphamide and total-body irradiation before transplantation for the treatment of acute nonlymphocytic leukemia.

This article has been cited by other articles:

• Bouligand, J., Deroussent, A., Simonnard, N., Opolon, P., Morizet, J., Connault, E., Daudigeos, E., Re, M., Paci, A., Vassal, G. (2007). Induction of Glutathione Synthesis Explains Pharmacodynamics of High-Dose Busulfan in Mice and Highlights Putative Mechanisms of Drug Interaction. Drug Metab. Dispos. 35: 306-314 [Abstract] [Full Text]  
• Gorin, N.-C., Labopin, M., Boiron, J.-M., Theorin, N., Littlewood, T., Slavin, S., Greinix, H., Cahn, J. Y., Alessandrino, E. P., Rambaldi, A., Nagler, A., Polge, E., Rocha, V. (2006). Results of Genoidentical Hemopoietic Stem Cell Transplantation With Reduced Intensity Conditioning for Acute Myelocytic Leukemia: Higher Doses of Stem Cells Infused Benefit Patients Receiving Transplants in Second Remission or Beyond--The Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. JCO 24: 3959-3966 [Abstract] [Full Text]  
• Copelan, E. A. (2006). Hematopoietic stem-cell transplantation.. NEJM 354: 1813-1826 [Full Text]  
• Matsumoto, T., Wada, H., Nishiyama, H., Hirano, T., Sakakura, M., Nishii, K., Masuya, M., Kageyama, S., Tamaki, S., Nakase, K., Nobori, T., Shiku, H. (2004). Hemostatic Abnormalities and Changes Following Bone Marrow Transplantation. CLIN APPL THROMB HEMOST 10: 341-350 [Abstract]  
• Srivastava, A., Poonkuzhali, B., Shaji, R. V., George, B., Mathews, V., Chandy, M., Krishnamoorthy, R. (2004). Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104: 1574-1577 [Abstract] [Full Text]  
• de Lima, M., Couriel, D., Thall, P. F., Wang, X., Madden, T., Jones, R., Shpall, E. J., Shahjahan, M., Pierre, B., Giralt, S., Korbling, M., Russell, J. A., Champlin, R. E., Andersson, B. S. (2004). Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104: 857-864 [Abstract] [Full Text]  
• Lund, M.B., Brinch, L., Kongerud, J., Boe, J. (2004). Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide. Eur Respir J 23: 901-905 [Abstract] [Full Text]  
• Askenasy, N., Yoleuk, E. S., Shirwan, H., Wang, Z., Farkas, D. L. (2003). Cardiac Allograft Acceptance after Localized Bone Marrow Transplantation by Isolated Limb Perfusion in Nonmyeloablated Recipients. Stem Cells 21: 200-207 [Abstract] [Full Text]  
• Tabbara, I. A., Zimmerman, K., Morgan, C., Nahleh, Z. (2002). Allogeneic Hematopoietic Stem Cell Transplantation: Complications and Results. Arch Intern Med 162: 1558-1566 [Abstract] [Full Text]  
• Tamaki, S., Wada, H., Ohfuzi, K., Shibata, T., Masuya, M., Kageyama, S., Gabazza, E. C., Kawakami, K., Tsuji, K., Miyanishi, E., Minami, N., Nobori, T., Shikut, H. (2002). Hemostatic Abnormalities Following Bone Marrow Transplantation. CLIN APPL THROMB HEMOST 8: 125-132 [Abstract]  
• Askenasy, N. (2002). Localized Bone Marrow Transplantation Leads to Skin Allograft Acceptance in Nonmyeloablated Recipients: Comparison of Intra-Bone Marrow and Isolated Limb Perfusion. Stem Cells 20: 86-93 [Abstract] [Full Text]  
• Socie, G., Clift, R. A., Blaise, D., Devergie, A., Ringden, O., Martin, P. J., Remberger, M., Deeg, H. J., Ruutu, T., Michallet, M., Sullivan, K. M., Chevret, S. (2001). Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 98: 3569-3574 [Abstract] [Full Text]  
• Leung, A. Y. H., Suen, C. K. M., Lie, A. K. W., Liang, R. H. S., Yuen, K. Y., Kwong, Y. L. (2001). Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood 98: 1971-1978 [Abstract] [Full Text]  
• Witherspoon, R. P., Deeg, H. J., Storer, B., Anasetti, C., Storb, R., Appelbaum, F. R. (2001). Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia. JCO 19: 2134-2141 [Abstract] [Full Text]  
• Balasubramanian, P., Srivastava, A., Chandy, M. (2001). Stability of Busulfan in Frozen Plasma and Whole Blood Samples. Clin. Chem. 47: 766-768 [Full Text]  
• Poonkuzhali, B., Chandy, M., Srivastava, A., Dennison, D., Krishnamoorthy, R. (2001). Glutathione S-Transferase Activity Influences Busulfan Pharmacokinetics in Patients with Beta Thalassemia Major Undergoing Bone Marrow Transplantation. Drug Metab. Dispos. 29: 264-267 [Abstract] [Full Text]  
• Weinberg, K., Blazar, B. R., Wagner, J. E., Agura, E., Hill, B. J., Smogorzewska, M., Koup, R. A., Betts, M. R., Collins, R. H., Douek, D. C. (2001). Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 97: 1458-1466 [Abstract] [Full Text]  
• Blaise, D., Kuentz, M., Fortanier, C., Bourhis, J. H., Milpied, N., Sutton, L., Jouet, J.-P., Attal, M., Bordigoni, P., Cahn, J.-Y., Boiron, J.-M., Schuller, M.-P., Moatti, J.-P., Michallet, M. (2000). Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Societe Francaise de Greffe de Moelle. JCO 18: 537-537 [Abstract] [Full Text]  
• Davies, S. M., Ramsay, N. K. C., Klein, J. P., Weisdorf, D. J., Bolwell, B., Cahn, J.-Y., Camitta, B. M., Gale, R. P., Giralt, S., Heilmann, C., Henslee-Downey, P. J., Herzig, R. H., Hutchinson, R., Keating, A., Lazarus, H. M., Milone, G. A., Neudorf, S., Perez, W. S., Powles, R. L., Prentice, H. G., Schiller, G., Socie, G., Vowels, M., Wiley, J., Yeager, A., Horowitz, M. M. (2000). Comparison of Preparative Regimens in Transplants for Children With Acute Lymphoblastic Leukemia. JCO 18: 340-340 [Abstract] [Full Text]  
• Parsons, S. K., Gelber, S., Cole, B. F., Ravindranath, Y., Ogden, A., Yeager, A. M., Chang, M., Shuster, J., Weinstein, H. J., Gelber, R. D. (1999). Quality-Adjusted Survival After Treatment for Acute Myeloid Leukemia in Childhood: A Q-TWiST Analysis of the Pediatric Oncology Group Study 8821. JCO 17: 2144-2144 [Abstract] [Full Text]  
• Ringden, O., Remberger, M., Ruutu, T., Nikoskelainen, J., Volin, L., Vindelov, L., Parkkali, T., Lenhoff, S., Sallerfors, B., Mellander, L., Ljungman, P., Jacobsen, N. (1999). Increased Risk of Chronic Graft-Versus-Host Disease, Obstructive Bronchiolitis, and Alopecia With Busulfan Versus Total Body Irradiation: Long-Term Results of a Randomized Trial in Allogeneic Marrow Recipients With Leukemia. Blood 93: 2196-2201 [Abstract] [Full Text]  
• Mittal, G, Balakrishna, C, Mangat, G, Joshi, V R (1999). 'Sustained remission' in a case of SLE following megadose cyclophosphamide. Lupus 8: 77-80 [Abstract]  
• Gorin, N.C. (1998). Autologous Stem Cell Transplantation in Acute Myelocytic Leukemia. Blood 92: 1073-1090 [Full Text]  
• Harousseau, J.-L., Cahn, J.-Y., Pignon, B., Witz, F., Milpied, N., Delain, M., Lioure, B., Lamy, T., Desablens, B., Guilhot, F., Caillot, D., Abgrall, J.-F., Francois, S., Briere, J., Guyotat, D., Casassus, P., Audhuy, B., Tellier, Z., Hurteloup, P., Herve, P. (1997). Comparison of Autologous Bone Marrow Transplantation and Intensive Chemotherapy as Postremission Therapy in Adult Acute Myeloid Leukemia. Blood 90: 2978-2986 [Abstract] [Full Text]  
• Zittoun, R. A., Mandelli, F., Willemze, R., de Witte, T., Labar, B., Resegotti, L., Leoni, F., Damasio, E., Visani, G., Papa, G., Caronia, F., Hayat, M., Stryckmans, P., Rotoli, B., Leoni, P., Peetermans, M. E., Dardenne, M., Vegna, M. L., Petti, M. C., Solbu, G., Suciu, S., The European Organization for Research and Treatme, (1995). Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia. NEJM 332: 217-223 [Abstract] [Full Text]  
• Armitage, J. O. (1994). Bone Marrow Transplantation. NEJM 330: 827-838 [Full Text]  
• Shannon, K. M., Cowan, M. J., Matthay, K. K. (1987). Pediatric Bone Marrow Transplantation: Intensive Care Management. J Intensive Care Med 2: 328-344 [Abstract]